U.S. market Closed. Opens in 1 day 11 hours 13 minutes

ROIV | Roivant Sciences Ltd. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 11.41 - 11.67
52 Week Range 9.69 - 13.06
Beta 1.49
Implied Volatility 45.10%
IV Rank 54.92%
Day's Volume 11,982,723
Average Volume 5,127,131
Shares Outstanding 727,950,000
Market Cap 8,422,381,500
Sector Healthcare
Industry Biotechnology
IPO Date 2020-12-08
Valuation
Profitability
Growth
Health
P/E Ratio 2.09
Forward P/E Ratio N/A
EPS 5.54
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 908
Country UK
Website ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
ROIV's peers: MRVI, KRYS, RXDX, AKRO, APLS, DAWN, PHAT, BPMC, LYRA, CGEM, ASND, BGNE, PLRX, SNDX, RVMD, VRDN, INZY, ZLAB
*Chart delayed
Analyzing fundamentals for ROIV we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is very wealthy, Growth is desperately bad and Health is weak. For more detailed analysis please see ROIV Fundamentals page.

Watching at ROIV technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on ROIV Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙